Mink Therapeutics, INC 10-Q quarterly reports

MiNK Therapeutics reported an increased net loss for Q3 2025, while highlighting promising clinical progress for its iNKT cell therapies and securing significant equity financing.

MiNK Therapeutics reported increased net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite advancing its iNKT cell therapy pipeline.

MiNK Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to liquidity challenges, despite ongoing clinical development and pipeline advancements.

MiNK Therapeutics reported its third quarter 2024 financial results, highlighting a decrease in operating expenses and advancements in its iNKT cell therapy programs.

MiNK Therapeutics reports a net loss of $6.5 million for the first six months of 2024, while highlighting progress in clinical trials and strategic collaborations.

MiNK Therapeutics reported a net loss of $3.8 million for the first quarter of 2024, while highlighting progress in its clinical programs and securing additional funding.